Drug intelligence / Profile preview

ABI-202

Development stage: Preclinical
Lead developer: Avirmax Biopharma
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Ophthalmic

Overview

ABI-202 is an investigational recombinant adeno-associated virus (rAAV) gene therapy being developed by Avirmax for the treatment of proliferative diabetic retinopathy (PDR). PDR is an advanced stage of diabetic eye disease characterized by the growth of abnormal new blood vessels (neovascularization) that can lead to severe vision loss, vitreous hemorrhage, and retinal detachment. ABI-202 utilizes Avirmax's proprietary AAV vector technology to deliver a therapeutic genetic payload directly to retinal cells, aiming to provide sustained therapeutic effect and reduce the treatment burden associated with frequent intravitreal injections of anti-VEGF agents. The program is currently in the IND-enabling stage of development.

Other names: ABI-202-Avirmax-rAAV gene therapyABI202-Avirmax-rAAV gene therapyABI 202-Avirmax-rAAV gene therapy

Targets

MAC (Complement membrane attack complex)C3 convertase (Ficolin-3)

Beyond the preview

Go deeper on ABI-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABI-202.

Explore the full profile